BioStem Technologies to Present at the Sidoti MicroCap Conference

Rhea-AI Summary

BioStem Technologies (Nasdaq: BSEM) announced that management will present at the Sidoti MicroCap Virtual Conference on Wednesday, August 19, 2026, at 10:45 AM ET. A live and archived webcast of the presentation will be available in the investors section of the company’s website.

BioStem develops, manufactures and commercializes perinatal tissue allograft products using its proprietary BioRetain, CryoTek and SteriTek processing technologies. Its allografts are used across multiple clinical specialties. The company highlights a growing product portfolio, expanding clinical research initiatives, a national commercial footprint, and accreditation by the Association for Advancing Tissue and Biologics, operating under cGTP and cGMP standards.

Market Context

BSEM's prior conference-call scheduling notice preceded a -2.44% 24-hour reaction, while this presen...

Analysis

BSEM's prior conference-call scheduling notice preceded a -2.44% 24-hour reaction, while this presentation notice adds no operating update. Recent filings reported a $9.0 million quarterly net loss, making subsequent company disclosures the key risk monitor.

Key Figures

Announcement date: August 14, 2026 Presentation date: August 19, 2026 Presentation time: 10:45 AM ET

3 metrics

Announcement date August 14, 2026 News announcement

Presentation date August 19, 2026 Sidoti MicroCap Virtual Conference

Presentation time 10:45 AM ET Sidoti MicroCap Virtual Conference

Historical Context

5 past events · Latest: Aug 12 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	Q2 earnings report	Negative	-18.4%	Q2 revenue and guidance update accompanied losses, cash decline, and a private placement.
Aug 06	Nasdaq uplisting	Positive	+1.8%	Nasdaq Capital Market listing approval preceded trading under the unchanged BSEM ticker.
Jul 29	Earnings call scheduling	Neutral	-2.4%	Conference call scheduling notice provided the August 12 results date and 4:30 PM webcast.
Jul 10	SEC registration filing	Neutral	+14.7%	SEC registration filing preceded planned Nasdaq listing and reported registration status.
Jul 08	Patent issuance	Positive	-0.8%	Four U.S. design patents covered the company's fenestrated human placental allograft technologies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across five recent events, reactions aligned with the event tone twice and diverged three times, indicating a mixed historical response.

Key Terms

allograft, current good tissue practices, current good manufacturing practices

3 terms

allograft medical

"development, manufacturing, and commercialization of perinatal tissue allograft products"

Tissue taken from one person and transplanted into another to repair or replace damaged body parts, such as bone, skin, or heart valves. For investors, allografts matter because their use involves manufacturing standards, supply and safety controls, regulatory approvals, and reimbursement rules that can affect sales, liability and growth for companies that process, store or sell these biological materials — similar to how sourcing and quality control of key parts affect a manufacturer’s business.

current good tissue practices regulatory

"established in compliance with current Good Tissue Practices"

A set of regulatory quality and safety rules that govern how human cells, tissues, and related medical products are collected, processed, stored, and tracked to prevent contamination, disease transmission, and mix-ups. Think of it like food-safety rules for biological material: it requires documented procedures, staff training, facility controls, donor screening, and recordkeeping. Investors care because compliance affects whether products can be sold, how inspections and recalls play out, and the legal and operational risks for a maker of tissue-based therapies.

current good manufacturing practices regulatory

"and current Good Manufacturing Practices"

Current good manufacturing practices (cGMPs) are the regulatory standards that govern how medicines, medical devices, and other regulated products must be made to ensure consistent safety, purity, and quality. Think of them as a strict recipe and kitchen rules—clean facilities, trained staff, documented steps, and quality checks—so each batch turns out the same. For investors, cGMP compliance reduces the risk of product recalls, regulatory fines, production shutdowns, and damage to long-term revenue and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual Conference.

BioStem is scheduled to present on Wednesday, August 19, 2026, at 10:45 AM ET. Interested parties may access live and archived webcasts of presentations on the “investors” section of the Company’s website at: ir.biostemtechnologies.com.

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
ir@biostemtech.com

Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com

FAQ

When will BioStem Technologies (Nasdaq: BSEM) present at the Sidoti MicroCap Virtual Conference in 2026?

BioStem Technologies is scheduled to present on Wednesday, August 19, 2026, at 10:45 AM ET. According to BioStem, the presentation is part of the Sidoti MicroCap Virtual Conference and will be accessible to interested investors via webcast.

How can investors access the BioStem Technologies (BSEM) presentation at the August 2026 Sidoti MicroCap Conference?

Investors can access live and archived webcasts of BioStem’s Sidoti MicroCap presentation through the investors section of its website at ir.biostemtechnologies.com. According to BioStem, the replay will remain available after the live event.

What does BioStem Technologies (BSEM) do in regenerative medicine?

BioStem Technologies develops, manufactures and commercializes advanced allograft products derived from perinatal tissue. According to BioStem, its proprietary BioRetain, CryoTek and SteriTek processing technologies are designed to preserve natural tissue properties for use across a wide range of clinical specialties.

Which product brands are in the BioStem Technologies (BSEM) allograft portfolio?

BioStem’s portfolio includes the Neox, Clarix, VENDAJE and American Amnion product lines. According to BioStem, these brands reflect its focus on perinatal tissue allograft solutions supporting clinical use in multiple medical specialties nationwide.

Is BioStem Technologies (BSEM) accredited for its tissue and biologics quality systems?

Yes. BioStem’s quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (AATB). According to BioStem, these systems comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP).

How can investors and stakeholders contact BioStem Technologies (BSEM) for investor relations?

Investor relations inquiries can be directed to Philip Trip Taylor, Gilmartin, via email at ir@biostemtech.com. According to BioStem, additional contact options and updates are available on its website and social media channels, including X and LinkedIn.

Where can I follow the latest BioStem Technologies (BSEM) news and updates?

Stakeholders can sign up for BioStem’s email distribution list on its website and follow the company on X at @BSEM_Tech and on LinkedIn. According to BioStem, these channels share corporate news, conference appearances and product-related updates.